Zheng ZX, Huang SM. Heterogeneous outcomes in metabolic dysfunction–associated steatotic liver disease/steatohepatitis with type 2 diabetes: Rethinking risk and management approaches. World J Clin Cases 2025; 13(29): 110771 [DOI: 10.12998/wjcc.v13.i29.110771]
Corresponding Author of This Article
Shu-Min Huang, MD, Fujian University of Traditional Chinese Medicine Affiliated Second People’s Hospital, No. 282 Gulou District, Fuzhou 35001, Fujian Province, China. 410292712@qq.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 16, 2025; 13(29): 110771 Published online Oct 16, 2025. doi: 10.12998/wjcc.v13.i29.110771
Heterogeneous outcomes in metabolic dysfunction–associated steatotic liver disease/steatohepatitis with type 2 diabetes: Rethinking risk and management approaches
Ze-Xu Zheng, Shu-Min Huang
Ze-Xu Zheng, Shu-Min Huang, Fujian University of Traditional Chinese Medicine Affiliated Second People’s Hospital, Fuzhou 35001, Fujian Province, China
Author contributions: Zheng ZX and Huang SM were responsible for the design of the study, writing the manuscript, revising the manuscript, and approving the final version; Zheng ZX and Huang SM agree to be accountable for all aspects of the work.
Conflict-of-interest statement: All author declares no relevant conflicts of interest related to this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shu-Min Huang, MD, Fujian University of Traditional Chinese Medicine Affiliated Second People’s Hospital, No. 282 Gulou District, Fuzhou 35001, Fujian Province, China. 410292712@qq.com
Received: June 16, 2025 Revised: June 30, 2025 Accepted: August 5, 2025 Published online: October 16, 2025 Processing time: 75 Days and 5.7 Hours
Abstract
Gosnell and colleagues executed a large-scale cohort investigation delineating ethnic disparities in outcomes among individuals with metabolic dysfunction–associated steatotic liver disease/steatohepatitis (MASLD/MASH). Uncovering such heterogeneity is pivotal to optimising management and prognostication, notably for hepatocellular carcinoma, fibrotic progression, and all-cause mortality. The authors furnish granular trajectories for Hispanic vs non-Hispanic populations across the United States and southeastern Texas, alongside a comprehensive appraisal of MASLD/MASH-related event rates. These insights provide an indispensable framework for early risk stratification and the tailoring of therapeutic algorithms and surveillance regimens. The study underscores the necessity for nuanced appreciation of MASLD/MASH outcome profiles and associated management strategies, while interrogating regional variation in disease burden, the benefits of integrated metabolic care, and the potential of lifestyle interventions to attenuate complications and improve prognosis.
Core Tip: The authors not only delineate, with granular precision, the clinical trajectories of Hispanic and non-Hispanic patients across the United States and the Gulf Coast of Texas, but also furnish a rigorous quantification of metabolic dysfunction–associated steatotic liver disease/steatohepatitis (MASLD/MASH) -related event rates. Their synthesis provides an invaluable scaffold for early risk stratification and the refinement of therapeutic and surveillance algorithms. This work underscores the imperative of nuanced appraisal of MASLD/MASH outcomes and bespoke management strategies, interrogating regional heterogeneity in disease burden, the merits of integrated metabolic care, and the potential of lifestyle modification to mitigate complications and enhance prognosis.
